BLCM logo

Bellicum Pharmaceuticals (BLCM) Stock

Profile

Full Name:

Bellicum Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 December 2014

Indexes:

Not included

Description:

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 05, 2020

Recent annual earnings:

Mar 12, 2020
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 06, 2020

Analyst ratings

Recent major analysts updates

16 Feb '22 Ladenburg Thalmann
Buy
25 Nov '20 Wells Fargo
Outperform
25 Nov '20 SunTrust Robinson Humphrey
Buy
25 Nov '20 Raymond James
Outperform
25 Nov '20 PiperJaffray
Overweight
25 Nov '20 Ladenburg Thalmann
Buy
25 Nov '20 Jefferies
25 Nov '20 Guggenheim
Neutral
25 Nov '20 Citigroup
Neutral
25 Nov '20 Cantor Fitzgerald
Buy

Screeners with BLCM included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Bellicum Pharmaceuticals?
  • What is the ticker symbol for Bellicum Pharmaceuticals?
  • Does Bellicum Pharmaceuticals pay dividends?
  • What sector is Bellicum Pharmaceuticals in?
  • What industry is Bellicum Pharmaceuticals in?
  • What country is Bellicum Pharmaceuticals based in?
  • When did Bellicum Pharmaceuticals go public?
  • Is Bellicum Pharmaceuticals in the S&P 500?
  • Is Bellicum Pharmaceuticals in the NASDAQ 100?
  • Is Bellicum Pharmaceuticals in the Dow Jones?
  • When was Bellicum Pharmaceuticals's last earnings report?
  • When does Bellicum Pharmaceuticals report earnings?
  • Should I buy Bellicum Pharmaceuticals stock now?

What is the primary business of Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

What is the ticker symbol for Bellicum Pharmaceuticals?

The ticker symbol for Bellicum Pharmaceuticals is NASDAQ:BLCM

Does Bellicum Pharmaceuticals pay dividends?

No, Bellicum Pharmaceuticals does not pay dividends

What sector is Bellicum Pharmaceuticals in?

Bellicum Pharmaceuticals is in the Healthcare sector

What industry is Bellicum Pharmaceuticals in?

Bellicum Pharmaceuticals is in the Biotechnology industry

What country is Bellicum Pharmaceuticals based in?

Bellicum Pharmaceuticals is headquartered in United States

When did Bellicum Pharmaceuticals go public?

Bellicum Pharmaceuticals's initial public offering (IPO) was on 18 December 2014

Is Bellicum Pharmaceuticals in the S&P 500?

No, Bellicum Pharmaceuticals is not included in the S&P 500 index

Is Bellicum Pharmaceuticals in the NASDAQ 100?

No, Bellicum Pharmaceuticals is not included in the NASDAQ 100 index

Is Bellicum Pharmaceuticals in the Dow Jones?

No, Bellicum Pharmaceuticals is not included in the Dow Jones index

When was Bellicum Pharmaceuticals's last earnings report?

Bellicum Pharmaceuticals's most recent earnings report was on 5 November 2020

When does Bellicum Pharmaceuticals report earnings?

The date for Bellicum Pharmaceuticals's next earnings report has not been announced yet

Should I buy Bellicum Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions